Essential thrombocythaemia (ET) has been reported rarely to cause coronary thrombosis, but the management is still undefined. A 63 year old woman with multivessel coronary thrombosis, acute myocardial infarction (MI), and no reflow in reperfused coronary artery in association with ET is presented. The patient's platelet count was only moderately raised at the onset of MI, but peripheral blood smear and bone marrow evaluation revealed clumping giant platelets and numerous large hyperploid megakaryocytes. Long term prophylaxis with antiplatelet agents in patients with ET is recommended, even if the platelet count is not largely raised. Cytoreductive treatment may also be effective for secondary prevention when thrombotic complications occur.
- essential thrombocythaemia
- coronary artery
- no reflow
Statistics from Altmetric.com
Essential thrombocythaemia (ET) is an acquired myeloproliferative disorder characterised by a consistently high platelet count and clinical tendencies to both haemorrhage and thrombosis. Fewer than 20 cases of angina pectoris and myocardial infarction (MI) have been reported in association with ET.1-6 We describe a case of ET presenting with multivessel coronary thrombosis, acute MI, and no reflow in reperfused artery.
A 63 year old woman, recently found to have thrombocytosis, was brought to our hospital two hours after the onset of acute back pain, radiating to the neck, and accompanied by nausea and vomiting, but no shortness of breath. For two weeks before admission, she had intermittent back pain that lasted between two and three minutes. The patient had no history of spontaneous bleeding, smoking, hypertension, hyperlipidaemia, diabetes mellitus, atrial fibrillation, or family history of coronary artery disease, but was mildly obese (body mass index 28.8 kg/m2), and received thyroid hormone because of chronic thyroiditis. The ECG showed anterolateral ST elevation and reciprocal ST depression in inferior leads, consistent with an acute anterolateral MI. Laboratory data showed 10.8 × 103/mm3 leukcocytosis without an increase of creatine kinase. Her platelet count was raised at 69 × 104/mm3 and her haemoglobin was 10.2 g/l.
Three hours after the onset of back pain, the patient was taken to the catheterisation laboratory. Coronary angiography revealed a filling defect on the ostial portion of the right coronary artery (fig 1A). The left anterior descending (LAD) coronary artery was occluded at the mid-portion (fig 1B). She was treated initially with intracoronary tissue plasminogen activator (640 × 104 IU). This resulted in TIMI 1 flow in the LAD. Angioplasty was performed using a 3 mm Scuba balloon catheter through a 7 F guiding catheter (Advanced Cardiovascular Systems Inc, California, USA) and a 0.014″ flexible guide wire, but caused coronary dissection. Then 3.5 × 18 mm gfx stent (Arterial Vascular Engineering, CA, USA) was successfully implanted. The occluded lesion improved significantly, but the perfusion delay in the LAD remained (no reflow, fig 1C). After these procedures, repeat angiography showed disappearance of the filling defect in the right coronary artery. Before the procedure, the patient received aspirin (81 mg) and ticlopidine (100 mg). Heparin (1 × 104 IU/day) and low molecular weight dextran (100 ml/h) were administered during and after the procedure. Peak serum creatine kinase was 4760 IU with an MB isozyme level of 483 IU.
The platelet count rose to a maximum of 113.8 × 104/mm3 two weeks after admission, without an initial drop. Oral busulfan was administered and then the platelet count fell to around 60 × 104/mm3(fig 2). Peripheral blood smear evaluation revealed clumping giant platelets with heterogeneous morphology. Bone marrow examination showed numerous large hyperploid megakaryocytes. Normal myelopoiesis and erythropoiesis were present. Cytogenetics were normal and no Philadelphia chromosome was detected.
At repeated angiography one month after the procedure, there were no thrombus-like filling defects or significant athelosclerotic lesions in the coronary arteries, and the coronary flow in LAD was not slow (fig1D and E). Left ventriculography showed anteroapical hypokinesis with left ventricular ejection fraction of 68%. She was discharged, without chest pain, with a platelet count of 60.6 × 104/mm3 and on aspirin (81 mg/day), ticlopidine (200 mg/day), and busulfan (2 mg/day). She developed no major bleeding complications.
ET has clinical tendencies to both haemorrhage and thrombosis. However, coronary thrombosis and acute MI have been observed rarely in ET compared with other myeloproliferative disorders (for example, polycythaemia vera).5
Several theories have been postulated for the cause of coronary thrombosis from thrombocytosis. These are: abnormal activation of the fibrynolytic system, enhanced platelet procoagulant activity, and increased plasma viscosity.3 4 Previous studies showed that platelet size, rather than the absolute platelet count, is correlated with thrombotic complications.7 In our patient, peripheral blood smear evaluation revealed clumping giant platelets although the initial platelet count was only moderately raised. Fagheret al described patients with acute MI who had an initial drop in platelet count followed by an increased and even thrombocytosis.8 They reported that in 25% of acute MI patients the platelet count increased by almost 70% three weeks after the onset. The transient rise of the platelet count in our patient after admission might be reactive, but there was no initial drop and the rise was over 100%. Therefore, it is possible that the platelets were more haemostatically active at the onset of coronary thrombosis.
The aggressive inhibition of platelet aggregation and production may play an important role in treating ET associated ischaemic syndromes with coronary thrombosis. Michaelset al used a glycoprotein IIb/IIIa receptor inhibitor, abciximab, for acute MI due to ET.4However, the use of antiplatelet agents in these patients has been suspected of inducing haemorrhage rather than preventing thrombosis. Rossi et al showed that a low dose of aspirin can reduce the coronary thrombosis without increasing bleeding complications.5 Our patient did not develop major haemorrhagic complications during treatment with aspirin and ticlopidine, probably because of the low dosage adopted. There are also recent data from randomised clinical trials showing hydroxyurea to be effective in preventing ET related thrombotic complications by keeping the platelet count < 60 × 104/mm3.9 In our patient, busulfan was used to reduce platelet production.
Our patient also had no reflow phenomenon after recanalisation of the LAD. Several mechanisms have been advocated for the no reflow phenomenon in animal models, and a major candidate is direct ischaemic microvascular injury. 10 Our patient had acute MI with angiographically normal coronary arteries. The obstruction of LAD does not appear to be due to the rupture of atherosclerotic plaque, but is likely to be transient thrombosis. Therefore, it is possible that multiple microvascular thrombi contributed, at least in part, to the no reflow phenomenon in our patient.
In conclusion, we recommend long term prophylaxis with antiplatelet agents in patients with ET, even if the platelet count is only moderately raised. Cytoreductive treatment in combination with antiplatelet agents may be effective for the second prevention when thrombotic complications occur.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.